CDNA - CareDx Inc Stock Price, Fair Value and News

$20.61+0.06 (+0.29%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CDNA Price Action

Last 7 days

-9.8%

Last 30 days

-7.9%

Last 90 days

-30.4%

Trailing 12 Months

76.3%

CDNA RSI Chart

CDNA Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-7.7

Price/Sales (Trailing)

3.53

EV/EBITDA

-7.84

Price/Free Cashflow

142.12

CDNA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CDNA Fundamentals

CDNA Revenue

Revenue (TTM)

312.8M

Rev. Growth (Yr)

23.35%

Rev. Growth (Qtr)

-10.18%

CDNA Earnings

Earnings (TTM)

-143.6M

Earnings Growth (Yr)

68.46%

Earnings Growth (Qtr)

-431.42%

CDNA Profitability

Operating Margin

83.49%

EBT Margin

-45.80%

Return on Equity

-52.54%

Return on Assets

-30.1%

Free Cashflow Yield

0.7%

CDNA Investor Care

Buy Backs (1Y)

0.86%

Diluted EPS (TTM)

-2.69

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	275.1M	297.1M	312.8M	0
2023	319.6M	309.3M	297.1M	280.3M
2022	308.4M	314.9M	318.6M	321.8M
2021	221.2M	253.6M	275.8M	296.4M
2020	139.5M	149.8M	169.4M	192.2M
2019	88.5M	102.1M	114.8M	127.1M
2018	50.8M	56.6M	65.6M	76.6M
2017	45.7M	47.0M	46.7M	48.3M
2016	27.5M	31.1M	36.4M	40.6M
2015	28.6M	29.0M	29.4M	28.1M
2014	23.0M	24.4M	25.2M	27.3M
2013	20.9M	21.3M	21.7M	22.1M
2012	0	0	0	20.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About CareDx Inc

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CEO	Dr. Reginald Seeto M.D., MBBS
WEBSITE	caredx.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	727

CareDx Inc Frequently Asked Questions

What is the ticker symbol for CareDx Inc? What does CDNA stand for in stocks?

CDNA is the stock ticker symbol of CareDx Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CareDx Inc (CDNA)?

As of Fri Dec 20 2024, market cap of CareDx Inc is 1.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDNA stock?

You can check CDNA's fair value in chart for subscribers.

Is CareDx Inc a good stock to buy?

The fair value guage provides a quick view whether CDNA is over valued or under valued. Whether CareDx Inc is cheap or expensive depends on the assumptions which impact CareDx Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDNA.

What is CareDx Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, CDNA's PE ratio (Price to Earnings) is -7.7 and Price to Sales (PS) ratio is 3.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDNA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CareDx Inc's stock?

In the past 10 years, CareDx Inc has provided 0.11 (multiply by 100 for percentage) rate of return.